FDA approves skin cancer vaccine by...?

The biggest reason to lean Yes is that the program has already cleared the hardest clinical hurdle. A positive Phase 3 result in a high-risk melanoma setting usually moves a product from speculative development into a realistic regulatory pathway, and this one is especially notable because it is being developed with a major oncology partner and has a clear clinical use case as adjuvant treatment after surgery. If the data package is strong enough to support a filing, FDA approval by the end of 2027 is very plausible, including approval in a narrower population or in combination with Keytruda.

The main uncertainty is not whether the science is interesting, but whether the regulatory and manufacturing process stays on schedule. The market description makes clear that the product is not yet approved and that, as of the latest reporting, the companies still need to submit the data and move through FDA review. For a personalized mRNA therapy, CMC, reproducibility, and logistics matter more than they do for a standard oncology drug, and those issues can slow the timeline even after a successful pivotal trial. A clean submission in 2026 or early 2027 would make approval by year-end 2027 very achievable, but any delay in filing, questions from FDA, or requests for additional analyses would reduce the odds materially.

The market price near 57.5% suggests traders already see a better-than-even chance, but not a near-certainty. That seems reasonable because the approval path is real yet still incomplete: the therapy has positive late-stage momentum, but it has not entered the final regulatory phase long enough to make approval almost locked in. Compared with a typical early-stage oncology story, this is much farther along and therefore deserves a higher-than-fifty chance; compared with an already-filed BLA awaiting action, it still carries more execution risk than the market might imply.